Opicapone
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Opicapone: From Parkinson’s Disease to Rasmussen Subacute Encephalitis
One-Sentence Summary
Opicapone is a peripheral COMT (catechol-O-methyltransferase) inhibitor, used as adjunctive therapy with levodopa in Parkinson’s disease. The TxGNN model’s top-ranked prediction is Rasmussen Subacute Encephalitis, but this pairing is currently supported by 0 clinical trials and 0 publications, and the model’s own rationale flags it as mechanistically implausible.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Parkinson’s disease (adjunct to levodopa/DOPA-decarboxylase inhibitor therapy) — inferred from mechanistic rationale text; not present as a structured field in this evidence pack |
| Predicted New Indication | Rasmussen Subacute Encephalitis |
| TxGNN Prediction Score | 98.64% |
| Evidence Level | L5 |
| EU/TW Market Status | ✗ Not marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available from the structured original_moa field (flagged as a Blocking/High data gap). Based on information embedded in the model’s own rationale text, Opicapone acts as a peripherally-restricted COMT inhibitor, reducing peripheral breakdown of levodopa to prolong central dopaminergic availability — its established role in Parkinson’s disease motor fluctuation management.
For the top-ranked prediction, this mechanistic link is explicitly weak. Rasmussen subacute encephalitis is a T-cell mediated autoimmune/inflammatory cortical encephalitis in children, a pathology with no known connection to COMT enzyme activity or catecholamine metabolism. The rationale itself states that the high TxGNN score likely reflects topological proximity of neurological-disease nodes in the knowledge graph, rather than genuine pharmacological plausibility — there is no clinical or mechanistic support for this pairing.
Notably, several lower-ranked candidates in this evidence pack show stronger biological rationale — particularly Lewy body dementia (rank 7, synucleinopathy overlap with Parkinson’s disease, flagged “Research Question”) and PLA2G6-associated neurodegeneration (rank 3, parkinsonian phenotype overlap, flagged “Research Question”). These may be more productive directions than the top-scored candidate for further investigation.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Safety Considerations
Please refer to the SmPC for safety information.
(Note: TFDA/EMA label warnings and contraindications are marked as a Blocking data gap (DG001) in this evidence pack — this must be resolved before any safety evaluation can proceed.)
Conclusion and Next Steps
Decision: Hold
Rationale: The top-ranked prediction (Rasmussen subacute encephalitis) has no clinical or literature evidence, and the model’s own mechanistic rationale explicitly disputes its pharmacological plausibility, attributing the high score to knowledge-graph topology rather than biology. This does not meet the bar to proceed.
To proceed, the following is needed:
- Resolve DG001 (TFDA/regulatory label — warnings, contraindications) — currently blocking any safety evaluation
- Resolve DG002 (confirmed mechanism of action from DrugBank or primary literature)
- Re-evaluate mechanistically stronger candidates from this same prediction set — particularly Lewy body dementia and PLA2G6-associated neurodegeneration — as alternative research questions
- If pursuing Rasmussen encephalitis specifically, obtain independent mechanistic or preclinical justification before any clinical consideration, given the model’s own caveat about graph-topology bias
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.